Abstract
Background: This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). Methods: Patients receiving >2 years of avelumab were reviewed and exploratory descriptive analyses were conducted. Results: Individuals with varying baseline characteristics who had received up to 6 years of avelumab were reviewed. Overall, 37/340 (10.9%) had received ≥2 years of treatment; in this subgroup, best response was complete response in 5.4%, partial response in 59.5% and stable disease in 29.7%; 51.4% had continued treatment beyond disease progression. Conclusions: In this study, 11% of patients with advanced non-small-cell lung cancer received ≥2 years of avelumab treatment and experienced prolonged response or continued clinical benefit.
Original language | English (US) |
---|---|
Pages (from-to) | 1333-1342 |
Number of pages | 10 |
Journal | Future Oncology |
Volume | 18 |
Issue number | 11 |
DOIs | |
State | Published - Apr 2022 |
Keywords
- Clinical trials
- Immunotherapy
- Lung
- Metastasis
- Solid tumors
ASJC Scopus subject areas
- Oncology
- Cancer Research